Novavax, Inc. (NVAX) fair value analysis
Nasdaq · Updated 2026-10-19
NVAX price how computed
Valuation status
No fair-value estimate yetNVAX has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for NVAX yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $11.26
- Sector
- Healthcare
- 12-month range
- $6.22–$12.82
- Market cap
- $1.86B
- From 52-week high
- -12.2%
- Shares outstanding
- 165M
- Rank in Healthcare by quality score
- #86 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Novavax, Inc. is a biotechnology company that develops and manufactures vaccines for infectious diseases. The company operates globally and is based in the United States.
NVAX currently ranks #86 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $1.86B
- P/E (trailing)
- n/m
- Revenue (TTM)
- $414M
- Net margin
- -59.9%
- EPS (TTM)
- $-0.74
- Gross margin
- 74.9%
- Debt / equity
- 0.00
- Revenue growth (3-yr avg)
- 52.3%
- Shares outstanding
- 165M
Derived indicators how computed
- Quality grade
- C
- Margin trend
- Expanding
- 52-week position
- The top quarter of its range
Technicals how computed
- RSI (14-day)
- 52 · neutral
- 50-day average
- $10.02
- 200-day average
- $9.16
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Earnings how computed
- Next earnings report
- 2026-11-05
- Last 8 quarters vs consensus
- 6 beat, 2 missed
- Quarter by quarter
- 2026-06 ▲ beat (+11.1%)
2026-03 ▲ beat (+83.8%)
2025-12 ▲ beat (+116.7%)
2025-09 ▲ beat (+58.4%)
2025-06 ▲ beat (+933.3%)
2025-03 ▲ beat (+312.7%)
2024-12 ▼ miss (-1.2%)
2024-09 ▼ miss (-1.3%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 5 buy · 1 hold · 3 sell (9 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $14.2
- Target vs last price
- +26.1%
What our data shows for NVAX
- Shares are trading in the upper third of their 12-month price range of $6.22–$12.82.
- The 14-day relative strength index sits at a neutral 52.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- NVAX's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the NVAX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — NVAX's relative strength index moved out of overbought territory into neutral zone this week. The healthcare sector company's derived indicators reflect this shift, though a complete valuation assessment remains pending. This technical adjustment suggests a moderation in recent price momentum.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — NVAX's Relative Strength Index has moved from the neutral zone into overbought territory this week, indicating increased upward momentum in the stock's recent price action. The Healthcare sector company remains under full valuation review, with no current valuation verdict established. This shift in the RSI reading reflects strengthened buying pressure over the past seven days.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is NVAX stock undervalued?
TickrTrends has no fair-value estimate for NVAX yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is NVAX's TickrTrends verdict?
NVAX is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does NVAX compare to other Healthcare stocks?
NVAX ranks #86 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is NVAX overbought or oversold?
NVAX's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does NVAX report earnings next?
NVAX's next earnings report is scheduled for 2026-11-05, per the published earnings calendar.
Does NVAX usually beat earnings estimates?
Over its last 8 reported quarters NVAX beat the consensus estimate 6 times and missed 2 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about NVAX?
Of 9 analysts covering NVAX, 5 rate it a buy, 1 a hold and 3 a sell - buy-leaning, with a consensus price target of $14.2 (+26.1% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.